These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 25446071)
1. Impact of cadmium, cobalt and nickel on sequence-specific DNA binding of p63 and p73 in vitro and in cells. Adámik M; Bažantová P; Navrátilová L; Polášková A; Pečinka P; Holaňová L; Tichý V; Brázdová M Biochem Biophys Res Commun; 2015 Jan; 456(1):29-34. PubMed ID: 25446071 [TBL] [Abstract][Full Text] [Related]
2. Redox state of p63 and p73 core domains regulates sequence-specific DNA binding. Tichý V; Navrátilová L; Adámik M; Fojta M; Brázdová M Biochem Biophys Res Commun; 2013 Apr; 433(4):445-9. PubMed ID: 23501101 [TBL] [Abstract][Full Text] [Related]
3. The p73 DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding. Patel S; Bui TT; Drake AF; Fraternali F; Nikolova PV Biochemistry; 2008 Mar; 47(10):3235-44. PubMed ID: 18260640 [TBL] [Abstract][Full Text] [Related]
4. p53 and p73 display common and distinct requirements for sequence specific binding to DNA. Lokshin M; Li Y; Gaiddon C; Prives C Nucleic Acids Res; 2007; 35(1):340-52. PubMed ID: 17170001 [TBL] [Abstract][Full Text] [Related]
5. Molecular basis of S100 proteins interacting with the p53 homologs p63 and p73. van Dieck J; Brandt T; Teufel DP; Veprintsev DB; Joerger AC; Fersht AR Oncogene; 2010 Apr; 29(14):2024-35. PubMed ID: 20140014 [TBL] [Abstract][Full Text] [Related]
6. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Gaiddon C; Lokshin M; Ahn J; Zhang T; Prives C Mol Cell Biol; 2001 Mar; 21(5):1874-87. PubMed ID: 11238924 [TBL] [Abstract][Full Text] [Related]
7. Crystal structures of the DNA-binding domain tetramer of the p53 tumor suppressor family member p73 bound to different full-site response elements. Ethayathulla AS; Nguyen HT; Viadiu H J Biol Chem; 2013 Feb; 288(7):4744-54. PubMed ID: 23243311 [TBL] [Abstract][Full Text] [Related]
9. Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues. Muttray AF; Cox RL; Reinisch CL; Baldwin SA Mar Biotechnol (NY); 2007; 9(2):217-30. PubMed ID: 17242983 [TBL] [Abstract][Full Text] [Related]
10. Evolution of functions within the p53/p63/p73 family. De Laurenzi V; Melino G Ann N Y Acad Sci; 2000; 926():90-100. PubMed ID: 11193045 [TBL] [Abstract][Full Text] [Related]
11. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73. Zdzalik M; Pustelny K; Kedracka-Krok S; Huben K; Pecak A; Wladyka B; Jankowski S; Dubin A; Potempa J; Dubin G Cell Cycle; 2010 Nov; 9(22):4584-91. PubMed ID: 21088494 [TBL] [Abstract][Full Text] [Related]
12. Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code. Ciribilli Y; Monti P; Bisio A; Nguyen HT; Ethayathulla AS; Ramos A; Foggetti G; Menichini P; Menendez D; Resnick MA; Viadiu H; Fronza G; Inga A Nucleic Acids Res; 2013 Oct; 41(18):8637-53. PubMed ID: 23892287 [TBL] [Abstract][Full Text] [Related]
13. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. Stros M; Ozaki T; Bacikova A; Kageyama H; Nakagawara A J Biol Chem; 2002 Mar; 277(9):7157-64. PubMed ID: 11748232 [TBL] [Abstract][Full Text] [Related]
14. Regulation of the Activity in the p53 Family Depends on the Organization of the Transactivation Domain. Krauskopf K; Gebel J; Kazemi S; Tuppi M; Löhr F; Schäfer B; Koch J; Güntert P; Dötsch V; Kehrloesser S Structure; 2018 Aug; 26(8):1091-1100.e4. PubMed ID: 30099987 [TBL] [Abstract][Full Text] [Related]
15. C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity. Sauer M; Bretz AC; Beinoraviciute-Kellner R; Beitzinger M; Burek C; Rosenwald A; Harms GS; Stiewe T Nucleic Acids Res; 2008 Apr; 36(6):1900-12. PubMed ID: 18267967 [TBL] [Abstract][Full Text] [Related]
16. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. Davison TS; Vagner C; Kaghad M; Ayed A; Caput D; Arrowsmith CH J Biol Chem; 1999 Jun; 274(26):18709-14. PubMed ID: 10373484 [TBL] [Abstract][Full Text] [Related]
17. DNA modification with cisplatin affects sequence-specific DNA binding of p53 and p73 proteins in a target site-dependent manner. Pivonková H; Pecinka P; Cesková P; Fojta M FEBS J; 2006 Oct; 273(20):4693-706. PubMed ID: 16981908 [TBL] [Abstract][Full Text] [Related]
18. Structural basis for ASPP2 recognition by the tumor suppressor p73. Canning P; von Delft F; Bullock AN J Mol Biol; 2012 Nov; 423(4):515-27. PubMed ID: 22917970 [TBL] [Abstract][Full Text] [Related]
19. Expression profiles of p53, p63, and p73 in benign salivary gland tumors. Weber A; Langhanki L; Schütz A; Gerstner A; Bootz F; Wittekind C; Tannapfel A Virchows Arch; 2002 Nov; 441(5):428-36. PubMed ID: 12447671 [TBL] [Abstract][Full Text] [Related]
20. Structural evolution of p53, p63, and p73: implication for heterotetramer formation. Joerger AC; Rajagopalan S; Natan E; Veprintsev DB; Robinson CV; Fersht AR Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17705-10. PubMed ID: 19815500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]